IP Library Granted Patent US 8,048,917
Granted Patent B2
US 8,048,917 · App. 11/110,909 · Granted Nov 1, 2011

Prodrugs of GABA analogs, compositions and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,917
App. No.
11/110,909
Granted
Nov 1, 2011
Kind
B2
Abstract

The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

Claims (42)

1. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle, wherein:

R 7 and R 14 are each hydrogen;

R 13 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and sec-butyl; and

R 25 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl, and 1,1-diethoxyethyl.

2. The pharmaceutical composition of claim 1 wherein R 13 is methyl.

3. The pharmaceutical composition of claim 1 , wherein R 25 is methyl, ethyl, n-propyl or isopropyl.

4. The pharmaceutical composition of any one of claims 1 - 3 which is an oral sustained release dosage form.

5. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

6. A salt of a compound having the formula:

7. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 5 and a pharmaceutically acceptable vehicle.

8. An oral sustained release dosage form comprising the compound or pharmaceutically acceptable salt of claim 5 and a pharmaceutically acceptable vehicle.

9. A pharmaceutical composition comprising a compound having the formula:

and a pharmaceutically acceptable vehicle.

10. An oral sustained release dosage form of the compound having the formula:

and a pharmaceutically acceptable vehicle.

11. A method of treating neuropathic pain, comprising administering the compound or pharmaceutically acceptable salt of claim 5 to a patient in need thereof.

12. A method of treating neuropathic pain, comprising administering the pharmaceutical composition of claim 7 or the oral sustained release dosage form of claim 8 to a patient in need thereof.

13. A method of treating anxiety, comprising administering the compound or pharmaceutically acceptable salt of claim 5 to a patient in need thereof.

14. A method of treating anxiety, comprising administering the pharmaceutical composition of claim 7 or the oral sustained release dosage form of claim 8 to a patient in need thereof.

15. A method of treating ethanol withdrawal syndrome, comprising administering the compound or pharmaceutically acceptable salt of claim 5 to a patient in need thereof.

16. A method of treating ethanol withdrawal syndrome, comprising administering the pharmaceutical composition of claim 7 or the oral sustained release dosage form of claim 8 , to a patient in need thereof.

17. A method of treating insomnia, comprising administering the compound or pharmaceutically acceptable salt of claim 5 to a patient in need thereof.

18. A method of treating insomnia, comprising administering the pharmaceutical composition of claim 7 or the oral sustained release dosage form of claim 8 to a patient in need thereof.

19. A method of treating epilepsy, comprising administering the compound or pharmaceutically acceptable salt of claim 5 to a patient in need thereof.

20. A method of treating epilepsy, comprising administering the pharmaceutical composition of claim 7 or the oral sustained release dosage form of claim 8 to a patient in need thereof.

21. A method of treating neuropathic pain, comprising administering the compound of formula:

to a patient in need thereof.

22. A method of treating neuropathic pain, comprising administering the pharmaceutical composition of claim 9 or the oral sustained release dosage form of claim 10 to a patient in need thereof.

23. A method of treating anxiety, comprising administering the compound of formula:

to a patient in need thereof.

24. A method of treating anxiety, comprising administering the pharmaceutical composition of claim 9 or the oral sustained release dosage form of claim 10 to a patient in need thereof.

25. A method of treating ethanol withdrawal syndrome, comprising administering the compound of formula:

to a patient in need thereof.

26. A method of treating ethanol withdrawal syndrome, comprising administering the pharmaceutical composition of claim 9 or the oral sustained release dosage form of claim 10 to a patient in need thereof.

27. A method of treating insomnia, comprising administering the compound of formula:

to a patient in need thereof.

28. A method of treating insomnia, comprising administering the pharmaceutical composition of claim 9 or the oral sustained release dosage form of claim 10 to a patient in need thereof.

29. A method of treating epilepsy, comprising administering the compound of formula:

to a patient in need thereof.

30. A method of treating epilepsy, comprising administering the pharmaceutical composition of claim 9 or the oral sustained release dosage form of claim 10 to a patient in need thereof.

Assignments (8)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
SECURITY INTEREST Recorded Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
SECURITY INTEREST Recorded Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2008
From: GALLOP, MARK A.; CUNDY, KENNETH C.; ZHOU, CINDY X.; YAO, FENMEI; XIANG, JIA-NING; OLLMAN, IAN R.; QUI, FAYANG GREGORY
To: XENOPORT, INC.
Reel/Frame 020395/0772 →